OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	98
Future options for long-acting HIV treatment and prevention	70
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	50
The sounds of silencing: dynamic epigenetic control of HIV latency	37
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	31
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	28
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	26
Harnessing natural killer cells to target HIV-1 persistence	26
Persistent elite controllers as the key model to identify permanent HIV remission	25
Loneliness and social isolation in people with HIV	23
Editorial introduction	23
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	22
Editorial introduction	22
Editorial introduction	22
Challenges towards an AIDS-free generation in Africa and Asia	19
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	19
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	18
New latency-promoting agents for a block-and-lock functional cure strategy	18
Balancing polypharmacy and comorbidity management: cardiovascular health	17
The origins of new SARS-COV-2 variants in immunocompromised individuals	17
Defining multimorbidity in people with HIV – what matters most?	17
Viral and immune predictors of HIV posttreatment control	14
Role of follicular homing natural killer cells in HIV infection	14
Mpox and the impact on people with HIV	13

Editorial introduction	13
Aging of adult lifetime survivors with perinatal HIV	12
Impact of coronavirus disease 2019 on co-morbidities in HIV	12
The multifaceted nature of HIV tissue reservoirs	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Obesity among women with HIV	11
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Renal adverse drug reactions	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Beyond criminalization: reconsidering HIV criminalization in an era of reform	10
The severity of COVID-19 across the spectrum of HIV	10
HIV and cardiovascular disease: the role of inflammation	10
Gender and sex considerations in HIV and bone health	10
Editorial: New drugs for HIV: quo vadis?	10
Broadly neutralizing antibodies for HIV treatment and cure approaches	10
Host factors predisposing to kidney disease in people with HIV	10
Editorial introduction	10
Persistent HIV-1 transcription during ART: time to reassess its significance?	9
HIV drug resistance in various body compartments	9
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	9
Causes and outcomes of hepatic fibrosis in persons living with HIV	9
Strategies to target the central nervous system HIV reservoir	9
Editorial: Is it time to implement injectable antiretroviral treatments globally?	8
Innovative models of care supporting people aging with HIV	8
Editorial introductions	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
HIV-1 subtypes and latent reservoirs	7
Editorial introductions	7
The pathogenesis of obesity in people living with HIV	7
Editorial introduction	7
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	7
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua	6
Role of islatravir in HIV treatment and prevention: an update	6
Whole person HIV services: a social science approach	6
Care of people aging with HIV in resource limited settings	6
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	6
Scaling up preexposure prophylaxis to maximize HIV prevention impact	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	6
Towards a molecular profile of antiretroviral therapy-free HIV remission	6